Inger Marie Jensen Hansen

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial

Kristin Kaasen Jørgensen, Inge Christoffer Olsen, Guro Løvik Goll et al. · The Lancet · 2017 · 789 citations

Oncology, Clinical Translation, Originator Infliximab +10

Rfx6 directs islet formation and insulin production in mice and humans

Stuart B. Smith, Hui‐Qi Qu, Nadine Taleb et al. · Nature · 2010 · 359 citations · Full text

Metabolic Syndrome, Insulin Production, Insulin Signaling +10

FRI0203 A SINGLE-CENTER INVESTIGATION ON THE PREVALENCE OF MALIGNANCIES IN PATIENTS WITH POLYMYALGIA RHEUMATICA AND GIANT CELL ARTERITIS BY WAY OF 18F-FDG PET/CT: A PROSPECTIVE COHORT STUDY

Amir Emamifar, Søren Hess, Oke Gerke et al. · Annals of the Rheumatic Diseases · 2020 · 324 citations · Full text

A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry

Bente Glintborg, Inge Juul Sørensen, Anne Gitte Loft et al. · Annals of the Rheumatic Diseases · 2017 · 245 citations

To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry

Bente Glintborg, Anne Gitte Loft, Emina Omerovic et al. · Annals of the Rheumatic Diseases · 2018 · 153 citations · Full text